scholarly journals B-ADRENOBLOCKERS IN THERAPY FOR ARTERIAL HYPERTENSION: ON THE WAY TO REASONABLE COMPROMISE

2012 ◽  
Vol 9 (4) ◽  
pp. 22-27
Author(s):  
N B Perepech ◽  
V D Shurygina
Keyword(s):  
United Kingdom ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Antihypertensive Agents ◽  
Optimal Combination ◽  
Efficacy And Safety ◽  
First Line ◽  
Hypertensive Patients ◽  
Individual Approach ◽  
Long Acting

The paper discusses the aspects of using b-adrenoblockers in the treatment of patients with arterial hypertension (AH). It discusses the reasons why United Kingdom experts have excluded b-adrenoblockers from the list of first-line antihypertensive drugs. The place of b-adrenoblockers is defined among other antihypertensive agents according to the European and Russian guidelines for the management of hypertensive patients. The authors show indications for the use of different b-adrenoblockers in patients with AH and underline the need for an individual approach to choosing a b-adrenoblocker and the expediency of administering long-acting cardioselective drugs as agents having an optimal combination of their efficacy and safety.

scholarly journals Efficacy of irbesartan in arterial hypertension and metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 53-56
Author(s):  
O D Ostroumova ◽  
A A Zykova ◽  
T A Polosova ◽  
O V Bondarets
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Receptor Blockers

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

scholarly journals DRUG UTILIZATION BASED ADRS MONITORING OF ANTIHYPERTENSIVE AGENTS PRESCRIBED IN AL-QUWAYIYAH GENERAL HOSPITAL, SAUDI ARABIA

2018 ◽  
Vol 10 (3) ◽  
pp. 22
Author(s):  
Md Salahuddin Ansari ◽  
Faisal Al-otaibi
Keyword(s):  
Saudi Arabia ◽  
Calcium Channel ◽  
General Hospital ◽  
Drug Utilization ◽  
Calcium Channel Blockers ◽  
Antihypertensive Drugs ◽  
Antihypertensive Agents ◽  
Channel Blockers ◽  
Hypertensive Patients ◽  
Patient Interviews

Objective: To monitor drug utilization based adverse drug reactions (ADRs) of antihypertensive agents prescribed in Al-Quwayiyah general hospital, Saudi Arabia.Methods: An open, non-comparative, observational study was conducted on hypertensive patients attending the medicine outpatient department of Al-Quwayyah general hospital, Al-Quwayyah, Saudi arabia. Data were collected by conducting patient interviews. Data were captured for adverse drug reaction monitoring based on Narinjo scale and WHO format.Results: 25 ADRs were observed out of 212 hypertensive patients. Incidence was found to be higher in patients more than 40 y age, and females experienced more ADRs (n = 16, 7.54%) than males, 9 (4.62%). Combination therapy was associated with more number of ADRs (64.0%) as against monotherapy (36.0%). Calcium channel blockers were found to be the most frequently associated drugs with ADRs (n = 8), followed by diuretics (n = 6), and β-blockers (n = 5). Among individual drugs, amlodipine was found to be the commonest drug associated with ADRs (n = 8), followed by torasemide (n = 4). ADRs associated with the central nervous system was found to be the most frequent (48.0%) followed by musculoskeletal complaints (20.0%) and respiratory system disorders (16.0%).Conclusion: ADRs were experienced by taking the antihypertensive drugs prescribed in Al-Quwayyah general hospital, Saudi arabia. The findings would be useful for physicians in rational prescribing. Calcium channel blockers were found to be the most frequently associated drugs with ADRs.

scholarly journals New targets and old therapies for arterial hypertension

2019 ◽  
pp. 46-52
Author(s):  
S. R. Gilyarevsky ◽  
N. G. Bendeliani ◽  
M. V. Golshmid ◽  
G. Yu. Zakharova ◽  
I. M. Kuzmina ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Arterial Hypertension ◽  
Randomized Clinical Trials ◽  
Antihypertensive Drugs ◽  
Experimental Studies ◽  
The Elderly ◽  
Published Data ◽  
Efficacy And Safety ◽  
Adoption And Implementation ◽  
Moderate Cognitive Impairment

The article discusses approaches to the choice of antihypertensive drugs, which may be based on the adoption and implementation of new clinical guidelines for the management of patients with arterial hypertension. This paper provides data on the efficacy and safety of candesartan, an antihypertensive drug, which advantages were identified during a large number of randomized clinical trials. It discusses the recently published data on the effectiveness of more intensive regimens of antihypertensive therapy to reduce the risk of moderate cognitive impairment in patients with arterial hypertension. In this regard, the authors provide data of the previously completed studies, which showed the effect of candesartan on the rate of cognitive decline in patients with arterial hypertension in the elderly and senile age. The features of the pharmacological characteristics of candesaratan that can remotely explain its clinical efficacy are considered. The data of experimental studies of candesartan in animals, which contribute to the concept of the possible effects of candesartan, are presented.

scholarly journals Suboptimal Adherence to Antihypertensive Treatment: Causes and Management

2018 ◽  
Vol 10 (1) ◽  
pp. 41-45
Author(s):  
Stelina Alkagiet ◽  
Konstantinos Tziomalos
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Treatment ◽  
Antihypertensive Agents ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Treatment Regimens ◽  
Achieve Blood Pressure ◽  
Increased Risk ◽  
Suboptimal Adherence ◽  
Long Acting

Suboptimal adherence to antihypertensive treatment is very common and is associated with poor control of blood pressure and increased risk for cardiovascular events. Therefore, frequent evaluation of compliance is essential in all hypertensive patients. Simplifying treatment regimens, using fixed-dose combinations and long-acting agents improves adherence, facilitates achievement of treatment targets and reduces cardiovascular morbidity and healthcare expenditures. Accordingly, physicians should be educated to implement these changes in hypertensive patients, particularly in those who require multiple antihypertensive agents to achieve blood pressure controls and in those who receive additional medications for comorbidities.

scholarly journals Fleita is a Russian randomized, open-label, multicenter, comparative program for the evaluation of the efficacy and safety of the fixed combination drug Tarka (ABBOTT Laboratories, USA) versus optional sustained-release antihypertensive drugs in the treatment of patients with arterial hypertension and cognitive disorders (stepwise strategy)

2009 ◽  
Vol 6 (4) ◽  
pp. 34-34
Author(s):  
Irina Evgen'evna Chazova ◽  
Ol'ga Dmitrievna Ostroumova
Keyword(s):  
Sustained Release ◽  
Arterial Hypertension ◽  
Cognitive Functions ◽  
Antihypertensive Drugs ◽  
Cognitive Disorders ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Open Label ◽  
Combination Drug ◽  
The Impact

Lesion of the brain as a target organ in arterial hypertension (AH) is manifested not only by strokes, but also impaired cognitive functions. A number of foreign studies have revealed an independent association of death with cognitive impairment in elderly patients. However, the impact of AH on higher mental functions, including that in geriatric patients, has been little studied so far. The effect of antihypertensive drugs, including their fixed-dose combinations that are to be preferred in the pharmacotherapy of AH due to their high efficacy and safety, on cognitive functions also remains to be investigated. In this connection, the Russian FLEITA randomized, open-label, multicenter, comparative program for the evaluation of the efficacy and safety of the fixed-dose combination drug Tarka (ABBOTT Laboratories, USA) versus optional sustained-release antihypertensive drugs in the treatment of patients with arterial hypertension and cognitive disorders (stepwise strategy), its national coordinator being Professor I.E. Chazova, is being implemented under the aegis of the Russian Medical AH Society. The objective of the clinical FLEITA program is to study the clinical efficacy, tolerance, and safety of Tarka used in patients with AH and cognitive disorders. The paper also gives the task of the study, inclusion/exclusion criteria, and the design of the program.

Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom

2021 ◽  
Author(s):  
Tianze Jiao ◽  
Robert W Platt ◽  
Antonios Douros ◽  
Kristian B Filion
Keyword(s):  
United Kingdom ◽  
Primary Prevention ◽  
Antihypertensive Drug ◽  
Ace Inhibitors ◽  
Antihypertensive Drugs ◽  
First Line ◽  
Prescription Patterns ◽  
First Line Therapy ◽  
The United Kingdom ◽  
Line Therapy

Abstract BACKGROUND Several antihypertensive drugs are available for the primary prevention of cardiovascular disease (CVD). However, existing evidence on prescription patterns was primarily generated among patients at high CVD risk with short-term follow-up, and failed to capture impacts of time and patient characteristics. Our objective was therefore to describe longitudinal prescription patterns for antihypertensive drugs for the primary prevention of CVD among patients with arterial hypertension in the United Kingdom. METHODS This population-based cohort study used data from the Clinical Practice Research Datalink, included 660,545 patients with hypertension who initiated an antihypertensive drug between 1998 and 2018. Antihypertensive treatments were measured by drug class and described overall and in subgroups, focusing on first-line therapy (first antihypertensive drug(s) recorded after a diagnosis of hypertension) and second-line therapy (antihypertensive drug(s) prescribed as part of a treatment change following first-line therapy). RESULTS Angiotensin-converting enzyme (ACE) inhibitors (29.0%), thiazide diuretics (22.1%), and calcium-channel blockers (CCBs) (21.0%) were the most prescribed first-line therapies. ACE inhibitors have been increasingly prescribed as first-line therapy since 2001. Men were more likely to be prescribed ACE inhibitors than women (43.5% vs. 32.1%; difference: 11.4%; 95% confidence interval [CI], 11.0%–11.8%), and Black patients were more likely to be prescribed CCBs than White patients (63.6% vs. 37.0%; difference: 26.6%; 95% CI, 24.8%–28.4%). CONCLUSIONS Antihypertensive prescription patterns for the primary prevention of CVD among patients with hypertension are consistent with treatment guidelines that were in place during the study period, providing reassurance regarding the use of evidence-based prescribing.

RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: PREVALENCE, PROGNOSTIC SIGNIFICANCE, REASONS AND APPROACHES TO ANTIHYPERTENSIVE THERAPY

2019 ◽  
Vol 23 (1) ◽  
pp. 37-44 ◽  
Author(s):  
O. B. Kuzmin ◽  
V. V. Zhezha ◽  
L. N. Landar ◽  
O. A. Salova
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Resistant Hypertension ◽  
Antihypertensive Drugs ◽  
Refractory Hypertension ◽  
Hypertensive Patients

Arterial hypertension (AH) resistant to drug therapy is the phenotype of uncontrolled AH, in which patients receiving at least 3 antihypertensive drugs, including a diuretic, maintain blood pressure above the target level. Initially, the term refractory hypertension was also used to refer to resistant hypertension. Recently, however, refractory hypertension has been isolated into a separate phenotype of difficult to treat hypertension, which is defined as insufficient control of target blood pressure, despite the use of at least 5 different mechanisms of antihypertensive drugs, including long-acting diuretic and antagonist of mineralcorticoid receptors. Resistant hypertension is detected in 10–15 % of all hypertensive patients receiving drug therapy, and is often found in patients with chronic kidney disease. Hypertension can be a cause and/or consequence of kidney damage and is typical of most patients with chronic kidney disease. The lack of control of target blood pressure in a significant proportion of hypertensive patients with CKD who receive at least 3 antihypertensive drugs of different mechanisms of action indicates a lack of effectiveness of antihypertensive therapy, which not only accelerates the loss of renal function, but also significantly worsens the prognosis, contributing to such people risk of cardiovascular and renal complications. The review presents data on the prevalence, prognostic value of resistant hypertension in patients with chronic kidney disease, features of its formation and approaches to increasing the effectiveness of antihypertensive therapy in this patient population.

Advantages and Benefits of Once-Daily Nadolol Treatment in Hypertension

1982 ◽  
Vol 10 (5) ◽  
pp. 351-356
Author(s):  
Diego González
Keyword(s):  
Combination Therapy ◽  
Patient Compliance ◽  
Antihypertensive Therapy ◽  
Open Study ◽  
Antihypertensive Agents ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Treatment Of Hypertension ◽  
Therapeutic Responses

This multicentre, open study was conducted in 263 hypertensive patients from six different countries by seventeen investigators. The results confirm the efficacy and safety of nadolol, used alone or in combination therapy in the treatment of hypertension, even inpatients in whom previous antihypertensive therapy with other drugs was unsatisfactory. The study also demonstrated that nadolol can effectively replace a variety of other antihypertensive agents, and, because of once a day dosage, can enhance patient compliance and produce better therapeutic responses.

scholarly journals Antihypertensive efficacy of a fixed full-dose perindopril A-indapamide combination in patients with grades 2–3 arterial hypertension

2013 ◽  
Vol 10 (1) ◽  
pp. 66-69
Author(s):  
T V Glukhova ◽  
S A Solgalova ◽  
V V Alferov
Keyword(s):  
Blood Pressure ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Antihypertensive Drugs ◽  
Antihypertensive Agents ◽  
Antihypertensive Efficacy ◽  
Fixed Dose ◽  
Full Dose ◽  
Achieve Blood Pressure

Aim: to study the antihypertensive efficacy of a fixed full-dose perindopril arginine-indapamide combination in patients with grades 2–3 arterial hypertension (AH) who do not receive antihypertensive therapy or those who do not achieve blood pressure (BP) control with other antihypertensive drugs. Subjects and methods. The trial enrolled 30 patients: 20 (66,6%) males and 10 (33,3%) females aged 30 to 60 years (mean age 50,5±7,1 years). Grades 2 and 3 AH was recorded in 28 (93,3%) and 2 (6,6%) patients, respectively. According to office measurements, the baseline BP (systolic BP (SBP)/diastolic BP (DBP) averaged 169±13,3/100,3±6,9 mm Hg in the group. Before included into the trial, 25 (83,4%) patients had taken antihypertensive agents, of them 10 (40%) and 2 (5%) examinees had combination therapy and fixed-dose combinations, respectively. Results. During therapy with a fixed-dosed combination of perindopril arginine 10 mg and indapamide 2,5 mg, there was generally a trend for SBP and DPB to lower at week 2 of therapy and there was a significant reduction in SBP by 42,4±11,2 mm Hg and in DBP by 20,1±9,3 mm Hg by the end of month 3. The goal BP (lower than 140/90 mm Hg) was achieved in 96,6% of the patients. Conclusion. The fixed full-dose perindopril arginine-indapamide combination allows therapeutic efficiency to be enhanced in grades 2–3 AH patients having no target BP values.

Sign in / Sign up

Export Citation Format

Share Document